ABCL
Abcellera Biologics Inc. Health Care Pharmaceutical Preparations Russell 3000
$12.27Close
$3.7BMarket cap
$2.78 – $14.8252-week range
Nov 9, 2026Next report · after the close
Highlights
Strengths
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
- Volume drying up last 10 days 29% under the 50-day average
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
17%
1wk
up 3.8%
price change
1mo
down 15.9%
price change
12-month return
up 129%
market up 11% ·
its own up 107%
F-score
—
— Not assessed
Altman Z
5.76
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
3.8×
price / book
Earnings yield
down 6.1%
EBIT / enterprise value
Cheaper than
22%
of the market · expensive
Revenue growth
up 161%
year on year
EPS growth
—
latest quarter
Sales growth
down 76%
latest quarter · -173 pts
ROE
down 14%
return on equity
Free cash margin
down 232%
-$174.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
Repair signals
- Revenue reaccelerating (-24% then +161%)
Trade setup
ATR%
7.0%
$0.86 a day · 2×ATR $10.55
RS
99 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.8×
vs 50-day average
Up/down volume
1.08
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+8% vs market2 sessions after results
Financials
- Net -195%
- Free cash -232%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $233.2M | $375.2M | $485.4M | $38.0M | $28.8M | $75.1M |
| Operating income | $156.0M | $204.4M | $216.5M | -$237.2M | -$314.8M | -$217.1M |
| Net income | $118.9M | $153.5M | $158.5M | -$146.4M | -$162.9M | -$146.4M |
| Net margin | 51% | 41% | 33% | -385% | -565% | -195% |
| Earnings per share | $0.45 | $0.48 | $0.50 | -$0.51 | -$0.55 | -$0.49 |
| Free cash flow | $13.0M | $186.1M | $206.7M | -$120.8M | -$187.0M | -$174.1M |
| Free cash margin | 6% | 50% | 43% | -318% | -648% | -232% |
| Cash | $594.1M | $476.1M | $386.5M | $133.3M | $156.3M | $128.5M |
| Shareholders' equity | $830.5M | $1.0B | $1.2B | $1.2B | $1.1B | $966.9M |
| Shares outstanding | 269.50m | 283.26m | 286.85m | 290.82m | 295.76m | 300.60m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Feb 24, 2026 | Annual ↗ | Dec 31, 2025 | 55d |
| Nov 6, 2025 | Quarterly ↗ | Sep 30, 2025 | 37d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 4, 2024 | Quarterly ↗ | Sep 30, 2024 | 35d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Feb 20, 2024 | Annual ↗ | Dec 31, 2023 | 51d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 13, 2026 | Material agreement · Other events ↗ |
| Aug 10, 2026 | Regulation FD ↗ |
| Aug 7, 2026 | Other events ↗ |
| Aug 5, 2026 | Results · Regulation FD ↗ |
| Jul 29, 2026 | Other events ↗ |
| Jul 6, 2026 | Director or officer change ↗ |
| Jun 17, 2026 | Other events ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| Jun 5, 2026 | Director or officer change ↗ |
| May 11, 2026 | Results · Regulation FD ↗ |
| Feb 24, 2026 | Results · Regulation FD ↗ |
| Jan 14, 2026 | Regulation FD ↗ |